| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Bone and Mineral Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, New South Wales, Australia;
Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA; and
Department of Orthopaedics, Prince of Wales Hospital, Sydney, New South Wales
1Correspondence: Garvan Institute of Medical Research, 384 Victoria St., Darlinghurst, Sydney, New South Wales 2010, Australia. E-mail e.gardiner{at}garvan.unsw.edu.au
The microarchitecture of bone is regulated by complex interactions between the bone-forming and resorbing cells, and several compounds regulate both actions. For example, vitamin D, which is required for bone mineralization, also stimulates bone resorption. Transgenic mice overexpressing the vitamin D receptor solely in mature cells of the osteoblastic bone-forming lineage were generated to test the potential therapeutic value of shifting the balance of vitamin D activity in favor of bone formation. Cortical bone was 5% wider and 15% stronger in these mice due to a doubling of periosteal mineral apposition rate without altered body weight or calcium homeostatic hormone levels. A 20% increase in trabecular bone volume in transgenic vertebrae was also observed, unexpectedly associated with a 30% reduction in resorption surface rather than greater bone formation. These findings indicate anabolic vitamin D activity in bone and identify a previously unknown pathway from mature osteoblastic cells to inhibit osteoclastic bone resorption, counterbalancing the known stimulatory action through immature osteoblastic cells. A therapeutic approach that both stimulates cortical anabolic and inhibits trabecular resorptive pathways would be ideal for treatment of osteoporosis and other osteopenic disorders.—Gardiner, E. M., Baldock, P. A., Thomas, G. P., Sims, N. A., Henderson, N. K., Hollis, B., White, C. P., Sunn, K. L., Morrison, N. A., Walsh, W. R., Eisman, J. A. Increased formation and decreased resorption of bone in mice with elevated vitamin D receptor in mature cells of the osteoblastic lineage.
Key Words: osteoclast • osteocyte • periosteum • uncoupling • turnover
This article has been cited by other articles:
|
|
 |
|
  R. Bouillon, G. Carmeliet, L. Verlinden, E. van Etten, A. Verstuyf, H. F. Luderer, L. Lieben, C. Mathieu, and M. Demay Vitamin D and Human Health: Lessons from Vitamin D Receptor Null Mice Endocr. Rev., October 1, 2008; 29(6): 726 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Johnston, S. Andrews, V. Shen, F. Cosman, R. Lindsay, D. W. Dempster, and A. Iida-Klein The Effects of Combination of Alendronate and Human Parathyroid Hormone(1 34) on Bone Strength Are Synergistic in the Lumbar Vertebra and Additive in the Femur of C57BL/6J Mice Endocrinology, September 1, 2007; 148(9): 4466 - 4474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. Baldock, S. J. Allison, P. Lundberg, N. J. Lee, K. Slack, E.-J. D. Lin, R. F. Enriquez, M. M. McDonald, L. Zhang, M. J. During, et al. Novel Role of Y1 Receptors in the Coordinated Regulation of Bone and Energy Homeostasis J. Biol. Chem., June 29, 2007; 282(26): 19092 - 19102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Xue, A. C. Karaplis, G. N. Hendy, D. Goltzman, and D. Miao Exogenous 1,25-Dihydroxyvitamin D3 Exerts a Skeletal Anabolic Effect and Improves Mineral Ion Homeostasis in Mice that Are Homozygous for Both the 1{alpha}-Hydroxylase and Parathyroid Hormone Null Alleles Endocrinology, October 1, 2006; 147(10): 4801 - 4810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. O'Brien, R. L. Jilka, Q. Fu, S. Stewart, R. S. Weinstein, and S. C. Manolagas IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice Am J Physiol Endocrinol Metab, November 1, 2005; 289(5): E784 - E793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Duque, M. Macoritto, N. Dion, L.-G. Ste-Marie, and R. Kremer 1,25(OH)2D3 acts as a bone-forming agent in the hormone-independent senescence-accelerated mouse (SAM-P/6) Am J Physiol Endocrinol Metab, April 1, 2005; 288(4): E723 - E730. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Fitzpatrick, E. Buzas, T. J. Gagne, A. Nagy, C. Horvath, V. Ferencz, A. Mester, B. Kari, M. Ruan, A. Falus, et al. Targeted deletion of histidine decarboxylase gene in mice increases bone formation and protects against ovariectomy-induced bone loss PNAS, May 13, 2003; 100(10): 6027 - 6032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Huening, G. Yehia, C. A. Molina, and S. Christakos Evidence for a Regulatory Role of Inducible cAMP Early Repressor in Protein Kinase A-Mediated Enhancement of Vitamin D Receptor Expression and Modulation of Hormone Action Mol. Endocrinol., September 1, 2002; 16(9): 2052 - 2064. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Peacock, C. H. Turner, M. J. Econs, and T. Foroud Genetics of Osteoporosis Endocr. Rev., June 1, 2002; 23(3): 303 - 326. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
